Connective tissue diseases: Evaluation of clinical response

Rheumatology

Volumn 45, Issue SUPPL. 3, 2006, Pages

  Fischer Betz, Rebecca ^a   Schneider, M ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG TARGETING; DRUG USE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL SOCIETY; MIXED CONNECTIVE TISSUE DISEASE; OUTCOMES RESEARCH; POLYMYOSITIS; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; SCORING SYSTEM; SHORT FORM 36; SKIN LUPUS ERYTHEMATOSUS; SYMPTOMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; VALIDATION STUDY;

CLINICAL TRIALS AS TOPIC; CONNECTIVE TISSUE DISEASES; ENDPOINT DETERMINATION; HUMANS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33749021071     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel281     Document Type: Article

References (12)

1. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: Consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. Lupus 2000;9:322-7.
2. Benivelli W, Vitali C, Isenberg DA et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research III. Development of a computerized clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992;10:549-54.
3. Hay E, Bacon P, Gordon C et al. The BILAG index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58.
4. Bombardier C, Gladman D, Urowitz M, Caron D, Chang C. The Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
5. Liang M, Socher S, Larson M, Schur P. Reliability and validity of six systems for the clinical assessment of disease activity in SLE. Arthritis Rheum 1989;32:1107-18.
6. Bae SC, Koh HK, Chang DK, Kim MH, Park JK, Kim SY. Reliability and validity of Systemic Lupus Activity Measure-revised (SLAM-R) for Measuring Clinical Disease Activity in Systemic Lupus Erythematosus. Lupus 2001;10:405-9.
7. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: Measures of overall disease activity. Arthritis Rheum 2004;50:3418-26.
8. Furst DE, Clements PJ, Steen VD et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998;25:84-8.
9. Albrecht J, Taylor L, Berlin JA et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005;125:889-94.
10. ACR Criteria for proliferative and membranous renal disease in SLE clinical trials. Arthritis Rheum (in press).
11. Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 2003;30:1630-47.
12. McLaughlin W, Sitbon O, Badesch DB et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-9.